Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Non Operating Income: 2016-2023

Historic Non Operating Income for UroGen Pharma (URGN) over the last 5 years, with Dec 2023 value amounting to -$715,000.

  • UroGen Pharma's Non Operating Income fell 79.65% to -$715,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$689,000, marking a year-over-year decrease of 161.98%. This contributed to the annual value of -$669,000 for FY2024, which is 2.90% up from last year.
  • As of Q4 2023, UroGen Pharma's Non Operating Income stood at -$715,000, which was down 1,107.04% from $71,000 recorded in Q3 2023.
  • In the past 5 years, UroGen Pharma's Non Operating Income ranged from a high of $989,000 in Q1 2019 and a low of -$715,000 during Q4 2023.
  • For the 3-year period, UroGen Pharma's Non Operating Income averaged around -$92,083, with its median value being -$15,500 (2021).
  • Examining YoY changes over the last 5 years, UroGen Pharma's Non Operating Income showed a top increase of 331.25% in 2022 and a maximum decrease of 416.88% in 2022.
  • Over the past 4 years, UroGen Pharma's Non Operating Income (Quarterly) stood at $989,000 in 2019, then reached -$77,000 in 2021, then plummeted by 416.88% to -$398,000 in 2022, then tumbled by 79.65% to -$715,000 in 2023.
  • Its Non Operating Income was -$715,000 in Q4 2023, compared to $71,000 in Q3 2023 and -$30,000 in Q2 2023.